INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involvingpaclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLC patients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. Patients were classified into four histology groups: squamous cell (SCC), adeno- (AC), large cell (LCC) and others including not otherwise specified (O/NOS) carcinoma. Logrank test was performed to compare overall survival (OS) and progression free survival (PFS) distributions according to histology as well as treatment. RESULTS: Of 1139 patients including 716 men and 423 women, AC was the most common subtype (56.8%), followed by SCC (19.7%), O/NOS (17.0%) and LCC (6.5%). Men were more likely to have SCC and women were more likely to have AC (p = 0.002). Among the four histology groups, there was no imbalance in regard to race, performance status, weight loss, brain metastasis or treatment. In each histology group, we found no significant difference in OS and PFS between the four chemotherapy regimens. Conversely, in each treatment arm, the survival outcome was similar between the four histology subtypes. CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLC patients treated with first-line platin-based doublets involvingpaclitaxel, docetaxel or gemcitabine.
RCT Entities:
INTRODUCTION: We conducted this analysis to determine whether survival of advanced NSCLCpatients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen. METHODS: We retrospectively analyzed data from E1594, a front-line phase III study in which advanced NSCLCpatients were randomized to receive one of four regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, and carboplatin-paclitaxel. Patients were classified into four histology groups: squamous cell (SCC), adeno- (AC), large cell (LCC) and others including not otherwise specified (O/NOS) carcinoma. Logrank test was performed to compare overall survival (OS) and progression free survival (PFS) distributions according to histology as well as treatment. RESULTS: Of 1139 patients including 716 men and 423 women, AC was the most common subtype (56.8%), followed by SCC (19.7%), O/NOS (17.0%) and LCC (6.5%). Men were more likely to have SCC and women were more likely to have AC (p = 0.002). Among the four histology groups, there was no imbalance in regard to race, performance status, weight loss, brain metastasis or treatment. In each histology group, we found no significant difference in OS and PFS between the four chemotherapy regimens. Conversely, in each treatment arm, the survival outcome was similar between the four histology subtypes. CONCLUSIONS: Our analysis suggests that histology does not predict survival benefit in advanced NSCLCpatients treated with first-line platin-based doublets involving paclitaxel, docetaxel or gemcitabine.
Authors: K Kelly; J Crowley; P A Bunn; C A Presant; P K Grevstad; C M Moinpour; S D Ramsey; A J Wozniak; G R Weiss; D F Moore; V K Israel; R B Livingston; D R Gandara Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: G V Scagliotti; F De Marinis; M Rinaldi; L Crinò; C Gridelli; S Ricci; E Matano; C Boni; M Marangolo; G Failla; G Altavilla; V Adamo; A Ceribelli; M Clerici; F Di Costanzo; L Frontini; M Tonato Journal: J Clin Oncol Date: 2002-11-01 Impact factor: 44.544
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Paolo Ceppi; Marco Volante; Silvia Saviozzi; Ida Rapa; Silvia Novello; Alberto Cambieri; Marco Lo Iacono; Susanna Cappia; Mauro Papotti; Giorgio V Scagliotti Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: Giorgio V Scagliotti; Filippo De Marinis; Massimo Rinaldi; Lucio Crinò; Cesare Gridelli; Sergio Ricci; Yan D Zhao; Astra M Liepa; Patrick Peterson; Maurizio Tonato Journal: J Thorac Oncol Date: 2009-12 Impact factor: 15.609
Authors: Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: E H Tan; J Rolski; T Grodzki; C P Schneider; U Gatzemeier; P Zatloukal; E Aitini; G Carteni; H Riska; Y H Tsai; R Abratt Journal: Ann Oncol Date: 2009-03-10 Impact factor: 32.976
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Lisa M Hess; Amy M DeLozier; Fanni Natanegara; Xiaofei Wang; Victoria Soldatenkova; Alan Brnabic; Stephen L Able; Jacqueline Brown Journal: J Thorac Dis Date: 2018-12 Impact factor: 2.895